Results 101 to 110 of about 1,494 (190)

Poster Sessions

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax

open access: yes, 2018
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy with dismal outcomes for which no standard therapy exists.
Hogdal, Leah J.   +16 more
core   +1 more source

Challenges and practical considerations in the management of blastic plasmacytoid dendritic cell neoplasm: A single-center experience

open access: yesLeukemia Research Reports
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare and often life-threatening complex hematologic malignancy that can commonly infiltrate the skin, lymph nodes, central nervous system, and bone marrow.
Haripriya Andanamala   +2 more
doaj   +1 more source

Publication Only

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Genome-wide DNA methylation-analysis of blastic plasmacytoid dendritic cell neoplasm identifies distinct molecular features

open access: yes
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) constitutes a rare and aggressive malignancy originating from plasmacytoid dendritic cells (pDCs) with a primarily cutaneous tropism followed by dissemination to the bone marrow and other organs.
Chteinberg, Emil,   +43 more
core   +1 more source

CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies

open access: yes, 2019
The interleukin-3 receptor alpha chain (IL-3R), more commonly referred to as CD123, is widely overexpressed in various hematological malignancies, including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia, hairy cell leukemia, Hodgkin ...
Testa, Castelli, Pelosi
core   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm–Current Insights

open access: yes, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare clonal hematologic malignancy of plasmacytoid dendritic cell precursors. The presentation and clinical course of BPDCN is widely heterogeneous and was most recently categorized as a distinct ...
Venugopal, Sangeetha   +4 more
core   +1 more source

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) international registry: Assessment of the allo-HCT outcomes

open access: yes
Background: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an underdiagnosed rare disease with poor outcomes and limited treatment options.
Attardi, Enrico   +42 more
core   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [PDF]

open access: yesEgyptian Journal of Hematology and Bone Marrow Transplantation, 2017
openaire   +1 more source

Home - About - Disclaimer - Privacy